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PARP1 is required for adhesion molecule expression in
atherogenesis
Abstract
AIMS: Atherosclerosis is the leading cause of death in Western societies and a chronic inflammatory
disease. However, the key mediators linking recruitment of inflammatory cells to atherogenesis remain
poorly defined. Poly(ADP-ribose) polymerase 1 (PARP1) is a nuclear enzyme, which plays a role in
acute inflammatory diseases. METHODS AND RESULTS: In order to test the role of PARP in
atherogenesis, we applied chronic pharmacological PARP inhibition or genetic PARP1 deletion in
atherosclerosis-prone apolipoprotein E-deficient mice and measured plaque formation, adhesion
molecules, and features of plaque vulnerability. After 12 weeks of high-cholesterol diet, plaque
formation in male apolipoprotein E-deficient mice was decreased by chronic inhibition of enzymatic
PARP activity or genetic deletion of PARP1 by 46 or 51%, respectively (P < 0.05, n >or= 9). PARP
inhibition or PARP1 deletion reduced PARP activity and diminished expression of inducible nitric oxide
synthase, vascular cell adhesion molecule-1, and P- and E-selectin. Furthermore, chronic PARP
inhibition reduced plaque macrophage (CD68) and T-cell infiltration (CD3), increased fibrous cap
thickness, and decreased necrotic core size and cell death (P < 0.05, n >or= 6). CONCLUSION: Our
data provide pharmacological and genetic evidence that endogenous PARP1 is required for
atherogenesis in vivo by increasing adhesion molecules with endothelial activation, enhancing
inflammation, and inducing features of plaque vulnerability. Thus, inhibition of PARP1 may represent a
promising therapeutic target in atherosclerosis.
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Abstract 
Aim: Atherosclerosis is the leading cause of death in Western societies and a chronic inflammatory 
disease. However, the key mediators linking recruitment of inflammatory cells to atherogenesis remain 
poorly defined. Poly(ADP-ribose) polymerase 1 (PARP1) is a nuclear enzyme that plays a role in acute 
inflammatory diseases. 
Methods: In order to test the role of PARP in atherogenesis, we applied chronic pharmacological PARP 
inhibition or genetic PARP1 deletion in atherosclerosis-prone apolipoprotein E-deficient mice and 
measured plaque formation, adhesion molecules, and features of plaque vulnerability. 
Results: After 12 weeks of high-cholesterol diet, plaque formation in male apolipoprotein E-deficient mice 
was decreased by chronic inhibition of enzymatic PARP activity or genetic deletion of PARP1 by 46 or 51 
%, respectively (P < 0.05, n ≥ 9). PARP inhibition or PARP1 deletion reduced PARP activity and 
diminished expression of inducible nitric oxide synthase (iNOS), vascular cell adhesion molecule-1 
(VCAM-1), P-, and E-selectin. Furthermore, chronic PARP inhibition reduced plaque macrophage (CD68) 
and T-cell infiltration (CD3), increased fibrous cap thickness, and decreased necrotic core size and cell 
death (P < 0.05, n ≥ 6). 
Conclusions: Our data provide pharmacological and genetic evidence that endogenous PARP1 is 
required for atherogenesis in vivo by increasing adhesion molecules with endothelial activation, enhancing 
inflammation, and inducing features of plaque vulnerability. Thus, inhibition of PARP1 may represent a 
promising therapeutic target in atherosclerosis. 
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Introduction 
Atherosclerosis is the primary cause of myocardial infarction and stroke and thereby the leading cause of 
death in Western countries. It is a chronic inflammatory disease resulting from the interaction between 
modified lipoproteins, activated endothelial cells, inflammatory cells, and elements of the arterial wall.1 
However, the key mediators of atherosclerosis that may represent effective therapeutic targets remain 
poorly defined. 
Mammalian poly(ADP-ribose)polymerase 1 (PARP1) is an abundant nuclear chromatin-associated 
protein. It belongs to a large family of enzymes that catalyze the transfer of ADP-ribose units from their 
substrate β-nicotinamide adenine dinucleotide (NAD+) covalently to themselves and other nuclear 
chromatin-associated proteins.2,3 Although PARP1 protein synthesis can be regulated in response to 
several stimuli, PARP1 is principally regulated via substrate interactions through its catalytic site. PARP1 
is activated by DNA strand breaks, and thus involved in DNA damage response pathways. In addition, 
PARP1 may induce cell dysfunction or necrosis by depleting cellular energy pools.3 
In vivo experiments using PARP1 deletion 4 or pharmacological inhibition of PARP demonstrate a role 
for PARP in acute inflammatory processes such as myocardial infarction 5,6, diabetes-induced endothelial 
dysfunction in mice 7, and lipopolysaccharide-induced septic shock.8 In contrast. much less is known 
about its role in chronic inflammatory diseases. 
As inflammation is crucially involved in atherosclerosis 1, we hypothesized that PARP1 is required for 
the formation of atherosclerotic plaques. Thus, we examined the effects of chronic PARP inhibition (by 
treatment with PJ34) and genetic PARP1 deletion on plaque formation in atherosclerosis-prone 
apolipoprotein E knockout (ApoE-/-) mice.9 We found that chronic pharmacological PARP inhibition and 
genetic deletion of PARP1 decreased atherosclerosis, reduced enzymatic PARP activity, and diminished 
expression of inducible nitric oxide synthase (iNOS) and adhesion molecules. Furthermore, 
pharmacological PARP inhibition reduced the number of plaque inflammatory cells and diminished 
features of plaque vulnerability. 
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Methods 
 
Animals 
Experiments with the PARP inhibitor PJ34 were performed using ApoE-/- mice 9 on a pure C57Bl/6J 
background. For the genetic experiments, PARP1-/- 4 mice (129SvEv background) were crossbred with 
ApoE-/- mice (C57Bl/6J background) in order to obtain ApoE-/- PARP1+/+ and ApoE-/- PARP1-/- mice that all 
had the identical mixed 129SvEv/ C57Bl/6J background. 
 
Mouse experiments and PARP inhibitor 
Male ApoE-/- mice 9 or ApoE-/- PARP1+/+ (n = 9) and ApoE-/- PARP1-/- (n = 10) mice were fed a high-
cholesterol diet (CD; 1.25% total cholesterol, D12108, Research Diets, New Brunswick, NJ, USA) for 
3 months starting at the age of 8 weeks. The pharmacological experiments were carried out as follows: 
After 4 weeks of diet, PJ34 [N-(6-oxo-5,6-dihydro-phenanthridin-2-yl)-N,Ndimethylacetamide, EMD 
Biosciences, San Diego, CA, USA], was administered via subcutaneous implantation of a custom-made 
pellet (Innovative Research of America, Sarasota, FL, USA); this pellet provided a continuous release of 
250 µg PJ34/day for 60 days (n = 25). We selected this dosage based on previous studies that provided 
PJ34 parenterally up to 3 weeks.10 Mice with implantation of pellets containing vehicle (placebo, n = 25) as 
well as age-matched C57Bl/6J wild-type mice (n = 26) served as negative controls. At 20 weeks of age, 
i.e. 8 weeks after pellet implantation, all animals were euthanized with an overdose of isoflurane (Abbott; 
Baar, Switzerland) inhalation for tissue harvesting. For the genetic experiments, wild-type mice with a 
129SvEv/ C57Bl/6J background were used as a control group. All animal experiments were approved by 
the local animal committee and performed in accordance with our institutional guidelines that conform to 
the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health 
(NIH Publication No. 85-23, revised 1996).  
 
Blood chemistry and hematology 
At the time of tissue harvesting, 0.5 to 1 ml of blood was drawn from the right ventricle with heparinized 
syringes, immediately centrifuged at 4°C, and the plasma stored at -80°C. Total cholesterol, triglycerides, 
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and free fatty acids were analyzed using the reagents TR13421, TR22421 (both Thermo Electron Clinical 
Chemistry & Automation Systems) and 994-75409 (Wako Chemicals GmbH, Neuss, Germany), as 
recommended by the manufacturer. The lipid distribution in plasma lipoprotein fractions was assessed by 
fast-performance liquid chromatography gel filtration with a Superose 6 HR 10/30 column (Pharmacia, 
Uppsala, Sweden).11 Plasma values of VCAM-1 (MVC00) and ICAM-1 (MIC100; both R&D Systems, Inc., 
Minneapolis, MN, USA) were determined using ELISA, and MCP-1, TNF-α, IFN-γ, and IL-6 using multiplex 
array systems (BD FACSArray Bioanalyzer System and Becton Dickinson Cytometric Bead Array Mouse 
Inflammation Kit 552364; BD Biosciences, Erembodegem, Belgium). For hematologic analyses, blood 
drawn from the right ventricle was transferred to vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ, 
USA) and analyzed within 6 hours. 
 
Tissue harvesting and processing 
After puncturing the left ventricle and cutting the right atrium, vessels were rinsed briefly with normal saline 
and the aorta was excised after removing adventitial tissue and fat. For en face analyses, thoraco-
abdominal aortae (from the left subclavian artery to the iliac bifurcation) were opened longitudinally.12 For 
histological examination, the aortic arch was embedded in OCT (optimal cutting temperature) compound 
(Tissue-Tek; Sakura, The Netherlands), frozen on dry ice, and stored at –80°C. For biochemical analyses, 
aortic arches were shock-frozen in liquid nitrogen and stored at -80°C. 
 
Western blotting 
This technique was performed according to standard procedures including stripping and re-probing of 
membranes as needed. The following primary antibodies were used: Polyclonal rabbit antibodies against 
PARP1 (ALX-210-619; Alexis Corporation, Lausen, Switzerland) and monoclonal mouse antibodies 
against poly-ADP-ribose (ALX-210-890; Alexis) as well as iNOS (clone 6; BD Biosciences Franklin Lakes, 
NJ, USA); primary monoclonal rat antibodies were applied to detect CD106 (VCAM-1, clone MCA1229; 
Serotec, Oxford, UK), CD62E (E-selectin, clone 10E9.6), CD62P (P-selectin, clone RB40.34; both BD 
Biosciences Pharmingen), and α-tubulin (clone B512; Sigma Chemical Co., St. Louis, MO, USA). 
Secondary peroxidase-labeled anti-species-specific IgG antibodies (Amersham Biosciences, GE 
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Healthcare Europe GmbH, Otelfingen, Switzerland) were diluted 1:4000 and incubated with the 
membranes for 1 h at room temperature (RT). Proteins were visualized after incubation of the membranes 
in SuperSignal West Femto Maximum Sensitivity Substrate for 5 min at RT. For PARP1 and α−tubulin, 
Enhanced Luminescent Substrate was used (Pierce Biotechnology, Inc., Lausanne, Switzerland). Protein 
expression was quantified using Scion ImageTM and expressed as ratio to tubulin or PARP1, respectively, 
after normalizing to WT values. 
 
En face plaque staining 
For quantification of atherosclerotic plaques, en face analysis of the thoraco-abdominal aorta was 
performed as described.12 Plaque area was visualized by fat staining (Oil-red O), photographed with a 
digital camera (Olympus DP70, 12.5 megapixels) that was mounted on an Olympus SZX951 microscope 
(Olympus Schweiz AG, Schwerzenbach, Switzerland), and quantified (Analysis 5; SoftImaging System, 
Munster, Germany).13 
 
Histological examination 
Plaque size and composition were analyzed in at least 4 serial longitudinal cryosections of the aortic arch 
(5 μm thickness, 50 μm intervals) that were thaw-mounted on glass slides (SuperFrostPlus; Menzel GmbH 
und Co., Braunschweig, Germany). A segment of the lesser curvature of the aortic arch was identified by 
dropping a perpendicular axis from the beginning of the innominate artery to the lesser curvature and 
following a 3-mm distance distal from this axis as described (Supplemental Figure 1).14 Fat content was 
measured by ORO staining. Collagen, fibrous cap thickness, and necrotic core size were analyzed by 
Elastica van Gieson (EVG) staining as described.15 All sections were photomicrographed with a digital 
camera (Olympus DP50-CU) mounted on an Olympus BX51 microscope, digitized and analyzed (Analysis 
5, SoftImaging System). 
 
Immunohistochemistry and immunofluorescence 
Acetone-fixed and rehydrated cryosections were incubated with primary antibodies for 30 min at RT. The 
staining of CD106, CD62E and CD62P was performed with the same primary antibodies as used for 
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Western blotting. Primary rat monoclonal antibodies were used to stain the following antigens: CD68 (FA-
11; Serotec), CD3 (KT3; Chemicon / Millipore, Billerica, MA, USA) and PCNA (PC10, Abcam, Cambridge, 
UK). iNOS was detected with polyclonal rabbit antibodies (Serotec). Primary antibodies were revealed by 
goat anti-species-specific immunoglobulin antibodies, followed by alkaline phosphatase-labeled donkey 
antibodies against goat immunoglobulins. Alkaline phosphatase was visualized using naphthol AS-BI 
phosphate and new fuchsin as substrate. Endogenous alkaline phosphatase was blocked by levamisole. 
Color reactions were performed at RT for 15 min with reagents from Sigma. Sections were counterstained 
with hemalum and coverslips mounted with glycerol and gelatine. Proliferation was determined by indirect 
fluorescent staining for proliferation cell nuclear antigen (PCNA) using a mouse monoclonal antibody 
(clone PC10; DakoCytomation, Glostrup, Denmark) followed by an Alexa Fluor 488 conjugated anti-mouse 
antibody as secondary reagent. Cell death was assessed via terminal deoxyribonucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL; Roche, Rotkreuz, Switzerland).16 Nuclei were stained by 4'-6-
diamidino-2-phenylindole (DAPI, Boehringer, Mannheim). 
 
Statistics 
Values are expressed as mean ± SEM. An unpaired Student t-test or ANOVA with post hoc Tukey’s test 
were used to compare results between different groups. Significance was accepted at the level of 
P < 0.05. 
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Results 
 
Plaque formation is reduced by chronic PARP inhibition or PARP1 deletion 
We examined the effects of chronic pharmacological inhibition of PARP (by treatment with the PARP 
inhibitor PJ34) and genetic PARP1 deletion on plaque formation in atherosclerosis-prone apolipoprotein E 
knockout (ApoE-/-) mice.9 After twelve weeks of a high-cholesterol diet, the average en face plaque area in 
ApoE-/- mice treated with PJ34 for eight weeks was reduced by 46% compared with the plaque area in 
placebo-treated ApoE-/- mice (n = 10, P = 0.002, Figure 1A, B). Similarly, atherosclerosis in PARP1-/- 
ApoE-/- mice decreased by 51% (n = 10, P = 0.039) compared with PARP1+/+ ApoE-/- mice (n = 9; Figure 
1C, D). ApoE-/- mice treated with PJ34 appeared healthy with the exception of 5 out of 25 mice that 
developed skin lesions; ApoE-/- mice with or without PARP1 deletion were healthy with the exception of 1 
out of 10 PARP1-/- ApoE-/- mice that developed a skin lesion (Supplemental Figure 5). 
 
PARP1 activity in atherosclerotic aortae is diminished by chronic PARP inhibition or PARP1 
deletion 
To ensure that effective PARP inhibition or PARP1 deletion was achieved in the target tissue, we 
analyzed lysates of aortic arches from a subset of the above mice for PARP1 expression and PARP 
activity. PARP1 expression did not differ between wild-type mice and placebo- or PJ34-treated ApoE-/- 
mice (Figure 2A). However, PARP1 activity was increased by a factor of three in aortae from placebo-
treated ApoE-/- mice compared with wild-type mice (P < 0.001), and markedly reduced in mice upon 
chronic treatment with PJ34 (P < 0.05 vs. wild-type and P < 0.001 vs. placebo) (Figure 2A, B). Similarly, 
aortic lysates from PARP1+/+ ApoE-/- mice exhibited increased PARP activity compared with lysates from 
wild-type mice. PARP activity and PARP1 expression were not detectable in PARP1-/- ApoE-/- mice. 
(Figure 2C, D).  
 
Plasma lipid distribution upon chronic PARP inhibition or PARP1 deletion 
In order to investigate PARP-mediated effects on plasma cholesterol, we measured levels of total 
cholesterol and subfractions. ApoE-/- mice on a high-cholesterol diet displayed markedly increased total 
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cholesterol levels compared with wild-type mice (Supplemental Table 1, Supplemental Figure 2A). 
However, there was no significant difference between PJ34- and placebo-treated ApoE-/- mice. 
Interestingly, total cholesterol levels were increased in PARP1-/- ApoE-/- compared with PARP1+/+ ApoE-/- 
mice. This increase affected particularly the intermediate-density lipoprotein (IDL) and LDL subfractions 
(Supplemental Table 2, Supplemental Figure 3A). 
 
Expression of adhesion molecules in atherosclerotic aortae is decreased by chronic PARP 
inhibition or PARP1 deletion 
To investigate the putative mechanisms mediating reduced plaque formation in PJ34-treated or PARP1-
deficient atherosclerotic mice, we analyzed protein expression of adhesion molecules in aortic arch lysates 
from the same groups of animals. E-selectin, P-selectin, VCAM-1, and iNOS were barely detectable in 
wild-type mice without atherosclerosis, but their expression was significantly induced in placebo-treated 
ApoE-/- mice with abundant atherosclerotic plaques (Figure 3A, B). Chronic treatment with PJ34 markedly 
decreased E-selectin, P-selectin, VCAM-1, and iNOS protein levels (Figure 3A, B). Complementary 
immunohistochemical stainings of aortic arches confirmed these findings (Supplemental Figure 4). In 
parallel, increased expression of E-selectin, P-selectin, VCAM-1, and iNOS was observed in aortic arch 
lysates from PARP1+/+ ApoE-/- mice, whereas these proteins were not detectable in PARP1-/- ApoE-/- mice 
(Figure 3C, D).  
 
Number of inflammatory cells and features of plaque vulnerability are reduced by chronic PARP 
inhibition 
Inflammation is not only crucial in the early stages of atherogenesis related to plaque initiation, but also 
contributes to progression of late atherosclerotic events implicated in advanced lesions and plaque 
vulnerability.17 Therefore, we quantified plaque inflammation in longitudinal sections of aortic arches of 
placebo- (n = 9) or PJ34-treated (n = 6) ApoE-/- mice (Supplemental Figure 1). Compared with placebo 
administration, chronic PJ34 treatment significantly decreased plaque areas (Oil-red O-stained areas, 
P = 0.021; Figure 4A), plaque macrophages (CD68-positive areas, P = 0.018; Figure 4B), and T-cells 
(CD3-positive areas, P = 0.043; Figure 4C).  
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To address whether PARP affects plaque stability, we assessed parameters of plaque vulnerability in 
serial longitudinal sections of aortic arches in placebo- or PJ34-treated ApoE-/- mice. Compared with 
placebo administration, chronic PJ34 treatment increased fibrous cap thickness (P = 0.023) and reduced 
the necrotic core diameter (P = 0.028; Figure 5A). Furthermore, there was a trend to increased collagen 
content of atherosclerotic plaques in PJ34-treated compared with placebo-treated ApoE-/- mice (P = 0.051; 
Figure 5A). Cell death was lower in PJ34-treated ApoE-/- mice (P = 0.027; Figure 5B), whereas 
proliferation remained unchanged (data not shown). 
 
Systemic mediators of inflammation are not affected by chronic PARP inhibition 
To compare above local with systemic parameters of inflammation, we determined levels of plasma 
inflammatory cytokines and blood hematology counts. Plasma analyses of the inflammatory markers 
monocyte chemoattractant protein-1 (MCP-1), interferon γ (IFN-γ), interleukin 6 (IL-6), VCAM-1, 
intracellular adhesion molecule 1 (ICAM-1), and tumor necrosis factor α  (TNF-α) showed no significant 
differences between placebo- and PJ34-treated ApoE-/- mice, or between PARP1+/+ ApoE-/- and PARP1-/- 
ApoE-/- mice. Overall blood leukocyte counts as well as blood monocytes, lymphocytes, and neutrophils 
were unchanged (Supplemental Tables 3, 4). 
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Discussion 
 
Our results provide both pharmacological and genetic evidence that PARP1 increases expression of 
adhesion molecules, promotes plaque inflammation, and induces features of plaque vulnerability. 
Specifically, we show that pharmacological inhibition of PARP via chronic PJ34 administration as well 
as genetic deficiency of PARP1 markedly decreased plaque formation in atherosclerosis, a chronic 
inflammatory disease. Our findings match previous reports that demonstrate the importance of PARP1 for 
acute inflammatory diseases.5,8,7,18,19 A most recent report shows beneficial effects of pharmacological 
PARP inhibition and PARP1 deletion on the development of atherosclerotic plaques in mice.20 The authors 
describe an inhibition of MCP-1 expression in atherosclerotic murine aortae, via an NFκB-dependent 
pathway. Beyond this study, we identified adhesion molecules as critical mediators of PARP inhibition or 
PARP1 deletion, leading to a reduction in inflammatory activity within the atherosclerotic plaque. 
Our results demonstrate that PARP activity was enhanced in aortae of atherosclerotic mice compared 
with non-diseased arteries of wild-type mice. Overall PARP activity in atherosclerotic aortae was markedly 
decreased upon chronic unspecific PARP inhibition with PJ34 and was not detectable in PARP1-/- ApoE-/- 
mice. Our observations further show a specific increase in PARP1 activity in atherogenesis. They suggest 
a subordinate role for other PARP isoforms in this process given the lack of PARP activity (generated by 
PARP isoforms other than PARP1) in PARP1-/- ApoE-/- mice. Thus, PARP1 is likely to be responsible for 
most of the effects attributed to the PARP family in atherogenesis. PARP is known to be activated via DNA 
damage mediated by free radicals and reactive oxygen species. Reactive oxygen species are widely 
present in inflammatory conditions such as atherosclerosis, and are therefore likely to be one of the key 
triggers of PARP activation in atherosclerotic lesions. 
Interestingly, PARP1 expression remained similar in non-diseased arteries from wild-type mice and in 
aortae from atherosclerotic mice treated with the PARP inhibitor or placebo. As expected, PARP1 
expression was undetectable in PARP1-/- ApoE-/- mice. Enhanced PARP1 expression has been described 
in human atherosclerotic specimens 21, but this discrepancy may be explained by species differences. 
High levels of plasma triglycerides or cholesterol, in particular low-density lipoprotein (LDL) 
cholesterol, are established clinical risk factors and key modulators of atherosclerosis.22 Interestingly, total 
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cholesterol levels were increased in PARP1-/- ApoE-/- compared with PARP1+/+ ApoE-/- mice. We consider 
this effect not relevant for atherogenesis as PARP1-/- ApoE-/- mice exhibited less atherosclerosis. 
Furthermore, pharmacological inhibition of PARP activity did not affect the lipid profile. It is known that a 
therapeutic agent may reduce atherogenesis independent of serum lipid levels. For example, Steffens et 
al have found a reduction in the progression of atherosclerosis in ApoE-/- mice treated with low dose of the 
phytochemical tetrahydrocannabinol.23 As in our study, this decrease in atherosclerosis was independent 
of serum cholesterol and triglyceride levels. 
PARP inhibition decreases the expression of pro-inflammatory genes such as inducible nitric oxide 
synthase (iNOS) and vascular cell adhesion molecule 1 (VCAM-1) in acute inflammatory conditions 10. 
Therefore, we studied inflammatory mediators such iNOS, VCAM-1, P-, and E-selectin in atherosclerotic 
ApoE-/- mice to delineate possible mechanisms of PARP-dependent atherogenesis. The expression of 
these mediators was markedly decreased by chronic pharmacological PARP inhibition and virtually 
abolished in the presence of PARP1 deficiency. Our results suggest that inhibition of PARP or deletion of 
PARP1 reduce plaque initiation and progression in atherosclerosis-prone mice by decreasing expression 
of adhesion molecules and iNOS. This setting would inhibit the recruitment of monocyte-derived 
macrophages and T-cells to atherosclerotic plaques. The importance of P-selectin 24, E-selectin 25, VCAM-
1 26, and iNOS 27 in atherogenesis is well documented. We propose that activation of these adhesion 
molecules may depend, at least in part, on PARP as a co-activator in NF-κB-mediated transcription. 28,29 
Because NF-κB is induced in atherosclerosis 1, our findings suggest that PARP1 may increase induction 
of adhesion molecules in atherosclerotic plaques via NF-κB. 
In accordance with the decreased expression of adhesion molecules by either chronic PARP inhibition 
or PARP1 deletion, we found a marked reduction of macrophages and T-cells in atherosclerotic plaques. 
These findings suggest that chronic pharmacological PARP inhibition reduces inflammatory cell 
recruitment resulting in fewer inflammatory cells in the subintimal space of aortae in ApoE-/- mice. In 
agreement, PARP inhibition has been shown to decrease the infiltration of neutrophils in response to 
acute zymosan-induced inflammation in mice and rats.30 Our blood counts and plasma cytokines imply 
that the changes in adhesion molecules and inflammatory cells in atherosclerotic aortae did not affect 
systemic parameters of inflammation. We speculate that the critical changes in PARP activity occur in 
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endothelial cells and monocytes/ macrophages, thereby leading to the decrease in adhesion molecules 
and iNOS in atherosclerotic lesions. The reduction of PARP activity may also affect progression of 
atherosclerosis via secondary mechanisms, independent of adhesion molecule expression. 
The reduced inflammation in response to chronic PARP inhibition is likely to explain the increased 
fibrous cap thickness and smaller necrotic core that are both features of increased plaque stability. In 
accordance with these findings, genetic deletion of the immune mediator CD156 or its inhibition by anti-
CD40 antibody decreases atherosclerosis progression and augments atherosclerotic plaque stability by 
decreasing plaque leukocyte content.14,15 In addition, we found reduced TUNEL-positive cells in advanced 
plaques of atherosclerotic mice treated with the PARP inhibitor. These findings suggest that increased 
PARP1 activity facilitates cell death in murine atherosclerotic lesions. In fact, in a stroke model, PARP1-
deficient mice exhibit a marked reduction in cortical necrosis.31 Complementary to our findings, increased 
smooth muscle cell death in murine atherosclerotic plaques induces features of plaque vulnerability.32 
These findings imply that chronic PARP inhibition enhances features of plaque stability. 
While most groups applying PJ34 or other PARP inhibitors have given the drug parenterally, oral 
application of PJ34 has also been demonstrated to protect against the deleterious effects of various 
inflammatory diseases. 8,10 Therefore, we conclude that PJ34 or related compounds are absorbable if 
given orally and we extrapolate that they should be effective when given to humans. However, from a 
clinical point of view, a specific PARP1 inhibitor – as opposed to an unspecific PARP inhibitor – seems 
more desirable for the following reasons: In our study, PARP1 deletion was sufficient to decrease aortic 
PARP activity and reduce atherogenesis in mice by about 50%. Thus, specific PARP1 inhibition should be 
sufficient to reproduce these effects in patients. In addition, specific inhibition is likely to induce less side 
effects. 
In our study, we found that chronic PARP inhibition induces skin lesions in about a fifth of PJ34-
treated ApoE-/- mice and in about a tenth of ApoE-/- PARP1-/- mice. Similarly, the development of skin 
lesions has previously been reported to occur in a third of older PARP1-deficient mice.4 These findings 
suggest a possible link between skin lesions and PARP inhibition or PARP1 deficiency. No such side 
effects, however, have been reported with newer generations of PARP inhibitors used in clinical 
studies.33,34 
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We conclude that endogenous PARP1 enhances atherogenesis by increasing adhesion molecule 
expression with endothelial activation, enhancing plaque inflammation with macrophages and T-cells, and 
by inducing features of plaque vulnerability. Thus, inhibition of enzymatic PARP1 activity may represent a 
promising therapeutic target in atherosclerosis. 
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Figure Legends 
 
Figure 1. Aortic plaque formation is reduced by chronic PARP inhibition or PARP1 deletion in 
ApoE-/- mice. (A) En face fat staining of thoracoabdominal aortae from ApoE-/- mice after 12 weeks of 
high-cholesterol diet; 8 weeks prior to harvesting, mice received placebo or PJ34. (B) Plaque formation 
was significantly decreased in PJ34-treated ApoE-/- mice (n = 10) compared with placebo-treated ApoE-/- 
mice (n = 10, *P = 0.002). (C) Fat staining of thoracoabdominal aortae from PARP1+/+ ApoE-/- or PARP1-/- 
ApoE-/- mice after 12 weeks of high-cholesterol diet. (D) Plaque formation was significantly reduced in 
PARP1-/- ApoE-/- mice (n = 10) compared with PARP1+/+ ApoE-/- mice (n = 9, *P = 0.039); unpaired two-
tailed Student t-test. Values are expressed as mean ± SEM. 
 
Figure 2. PARP activity in atherosclerotic aortae is diminished by chronic PARP inhibition or 
PARP1 deletion. (A, B) Western blots and graph showing PAR [poly(ADP)-ribose; a measure of PARP 
activity] and PARP1 protein in aortic arch lysates obtained from wild-type (WT), placebo-, or PJ34-treated 
ApoE-/- mice; α-tubulin served as internal control for protein loading. PARP activity is given as a ratio to 
PARP1 protein and normalized to WT values. n = 4 in each group. *P < 0.001; #P < 0.05. (C, D) Western 
blots and graph showing PAR and PARP1 protein (PARP1) in aortic arch lysates obtained from WT, 
PARP1+/+ ApoE-/-, or PARP1-/- ApoE-/- mice; α-tubulin served as internal control for protein loading. PARP 
activity is given as a ratio to PARP1 protein and normalized to WT values. n = 4 in each group. *P < 0.001; 
n/d, not detectable. One-way ANOVA with post-hoc Tukey’s test. Values are expressed as mean ± SEM. 
 
Figure 3. Expression of adhesion molecules in atherosclerotic aortae is decreased by chronic 
PARP inhibition or PARP1 deletion. (A) Western blots of E-selectin, P-selectin, VCAM-1, and iNOS in 
aortic arch lysates obtained from wild-type (WT), placebo-, or PJ34-treated ApoE-/- mice; n = 4 in each 
group. (B) Quantification of protein expression is given as ratio to α-tubulin (loading control) and 
normalized to WT. (C) Western blots of E-selectin, P-selectin, VCAM-1, and iNOS in aortic arch lysates 
obtained from WT, PARP1+/+ ApoE-/-, or PARP1-/- ApoE-/- mice. (D) Quantification of protein expression is 
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given as ratio to α-tubulin (loading control) and normalized to WT; n = 4 in each group. *P < 0.001; 
# P < 0.01; n/d, not detectable. One-way ANOVA with post hoc Tukey’s test. Values are expressed as 
mean ± SEM. 
 
Figure 4. Number of inflammatory cells is reduced by chronic PARP inhibition. Longitudinal aortic 
arch sections of placebo- (n = 9) or PJ34-treated (n = 6) ApoE-/- mice (left panels) stained with (A) Oil-red 
O (ORO), (B) antibodies against CD68, or (C) antibodies against CD3 (arrows pointing to positive 
stainings), with the corresponding quantifications (right panels). *P < 0.05; unparied two-tailed Student t-
test. Values are expressed as mean ± SEM. 
 
Figure 5. Features of plaque vulnerability are diminished by chronic PARP inhibition. Aortic arch 
sections of placebo- (n = 12) or PJ34-treated (n = 12) ApoE-/- mice stained with (A) Elastica van Gieson 
(EVG); quantifications of fibrous cap thickness (arrows), necrotic core diameter, *P < 0.05 (dashed line, 
bottom), and collagen content (P = 0.051). Aortic arch sections of placebo- or PJ34-treated ApoE-/- mice 
stained with (B) TUNEL, P = 0.027 (arrows indicating TUNEL-positive nuclei and their complementary 
DAPI stainings in the same sections) and the corresponding quantifications; unparied two-tailed Student t-
test. Bars =  50 μm. Values are expressed as mean ± SEM. 
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PARP1 is required for adhesion molecule expression in atherogenesis 
Supplemental Figures and Tables for Cardiovascular Research CVR/2007/868-R1 
 
Supplemental Figure 1. Histomorphological quantifications in longitudinal sections of the aortic 
arch. (A) A perpendicular axis (oblique dotted line) from the beginning of the inominate artery (horizontal 
dotted line) was dropped to the lesser curvature of the aortic arch. A 3 mm segment of the aortic wall from 
this axis towards the thoracic aorta was analyzed (continuous line). (B) Necrotic core size was determined 
at its largest diameter (dotted line). Fibrous cap thickness was determined at its shortest diameter (arrows) 
on top of the plaque; bars = 1 mm or 200 μm for the low or high magnification, respectively. 
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Supplemental Figure 2. No alterations of plasma lipid distribution in placebo- compared with PJ34-
treated ApoE-/- mice. Distribution of (A) cholesterol and (B) triglycerides in the plasma of wild-type mice 
(|, n = 5), placebo- (, n = 6) or PJ34-treated ApoE-/- mice (, n = 6). No differences in the distribution of 
cholesterol or triglycerides were detected between placebo- and PJ34-treated ApoE-/- mice. VLDL, very-
low-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; HDL, high-
density lipoprotein. 
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Supplemental Figure 3. Plasma lipid distribution in PARP1+/+ ApoE-/- and PARP1-/- ApoE-/- mice. 
Distribution of (A) cholesterol and (B) triglycerides in the plasma of wild-type mice (|, n = 5), PARP1+/+ 
ApoE-/- - (, n = 6) or PARP1-/- ApoE-/- mice (, n = 6). PARP1-/- ApoE-/- mice show increased IDL-LDL 
compared with PARP1+/+ ApoE-/- mice. VLDL, very-low-density lipoprotein; IDL, intermediate-density 
lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein. 
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Supplemental Figure 4. Localization of adhesion molecules and iNOS within plaques after placebo 
or chronic PARP inhibition. Longitudinal sections of aortic arches from ApoE-/- mice treated with placebo 
or PJ34 show increased expression of P-selectin, E-selectin, VCAM-1, and iNOS within atherosclerotic 
plaques (arrows indicating positive staining); n = 3 for each staining; bar = 100 μm. 
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Supplemental Figure 5. Skin lesions in atherosclerotic mice with pharmacological PARP inhibition 
or genetic PARP1 deletion. Skin lesions occur only in ApoE-/- mice treated with PJ34 or in PARP1-/- 
ApoE-/- mice, but not in ApoE-/- mice treated with Placebo or PARP1+/+ ApoE-/- mice (Table). (A) Unaffected 
skin of Placebo-treated animal. (B) Epidermal hyperplasia in the periphery of ulcer and (C) loss of 
epidermis in the center of ulcer (B and C are from the same PJ34-treated mouse); bar = 100 μm. 
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Supplemental Table 1. Plasma lipid profiles of wild-type, placebo-, and PJ34-treated ApoE-/- mice. 
 
 Wild-type (n = 5) 
Placebo ApoE-/-  
(n = 10) 
PJ34 ApoE-/-  
(n = 10) 
Total cholesterol 
(mmol/l) 3.1 ± 0.1 29.5 ± 4.1 
# 27.7 ± 5.0 # 
Triglycerides 
(mmol/l) 1.58 ± 0.11   0.65 ± 0.06 
§   0.86 ± 0.13 § 
Free fatty acids 
(mmol/l) 0.58 ± 0.03 0.88 ± 0.14 0.88 ± 0.12 
#P < 0.01 vs. wild-type, §P < 0.001 vs. wild-type. One-way ANOVA and post hoc Tukey’s test. Values are 
expressed as mean ± SEM. 
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Supplemental Table 2. Plasma lipid profiles of wild-type, PARP1+/+ ApoE-/-, and PARP1-/- ApoE-/- 
mice. 
 
 
 Wild-type (n = 5) 
PARP1+/+ ApoE-/-  
(n = 10) 
PARP1-/- ApoE-/-  
(n = 10) 
Total cholesterol 
(mmol/l) 1.3 ± 0.1 20.7 ± 2.1 
§ 31.2 ± 2.7 §, & 
Triglycerides 
(mmol/l) 0.78 ± 0.10 0.81 ± 0.10 1.32 ± 0.23 
Free fatty acids 
(mmol/l) 0.36 ± 0.03   0.92 ± 0.09 * 1.24 ± 0.13 
§ 
§P < 0.001 vs. wild-type, &P < 0.01 vs. PARP1+/+ ApoE-/-, *P < 0.05 vs. wild-type. One-way ANOVA and 
post hoc Tukey’s test. Values are expressed as mean ± SEM. 
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Supplemental Table 3. Cytokines and hematology values of wild-type, placebo-, and PJ34-treated 
ApoE-/- mice. 
 
 Wild-type (n = 5) 
Placebo ApoE-/-  
(n = 10) 
PJ34 ApoE-/-  
(n = 10) 
VCAM-1 
(ng/ml) 826 ± 17 1282 ± 96 *   1266 ± 107 * 
ICAM-1 
(ng/ml) 407 ± 17   780 ± 57 
#   776 ± 62 # 
MCP-1 
(pg/ml) 20.8 ± 3.1 49.4 ± 9.9 44.8 ± 6.2 
TNF-α 
(pg/ml) 8.4 ± 1.1 14.6 ± 2.0   16.6 ± 1.0 * 
IFN-γ 
(pg/ml) 2.0 ± 0.3 1.7 ± 0.3  1.6 ± 0.3 
IL-6 
(pg/ml) 2.6 ± 0.4 5.6 ± 1.2  9.3 ± 2.5 
    
 n = 6 n = 5 n = 5 
Leukocytes 
(103/µl) 3.8 ± 0.4 2.8 ± 0.3 3.5 ± 0.5 
Monocytes 
(103/µl) 0.54 ± 0.06 1.2 ± 0.2   1.3 ± 0.3 * 
Lymphocytes 
(103/µl) 2.9 ± 0.3   1.3 ± 0.1 
#  1.7 ± 0.4 * 
Neutrophils 
(103/µl) 0.11 ± 0.01 0.13 ± 0.02  0.1 ± 0.03 
 
*P < 0.05 vs. wild-type, #P < 0.01 vs. wild-type. One-way ANOVA and post hoc Tukey’s test. Values are 
expressed as mean ± SEM. 
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Supplemental Table 4. Cytokines and hematology values of wild-type, PARP1+/+ ApoE-/-, and 
PARP1-/- ApoE-/- mice. 
 
 
 Wild-type (n = 5) 
PARP1+/+ ApoE-/-  
(n = 10) 
PARP1-/- ApoE-/-  
(n = 10) 
VCAM-1 
(ng/ml) 899 ± 14 1208 ± 63 
# 1122 ± 45 * 
ICAM-1 
(ng/ml) 472 ± 12 848 ± 41 
§ 785 ± 30 § 
MCP-1 
(pg/ml) 40.2 ± 8.8 74.2 ± 21.3 79.2 ± 6.4 
TNF-α 
(pg/ml) 7.7 ± 3.7 18.0 ± 2.8 * 25.7 ± 1.5 
§ 
IFN-γ 
(pg/ml) 1.2 ± 0.4 1.4 ± 0.5 0.6 ± 0.1 
IL-6 
(pg/ml) 10.6 ± 3.4 18.3 ± 6.8 14.4 ± 2.8 
    
 n = 8 n = 5 n = 5 
Leukocytes 
(103/µl) 4.2 ± 0.3 6.1 ± 1.1 5.0 ± 0.5 
Monocytes 
(103/µl) 0.5 ± 0.07 1.9 ± 0.5 
# 2.3 ± 0.12 § 
Lymphocytes 
(103/µl) 3.3 ± 0.3 3.3 ± 0.6 2.1 ± 0.2 
Neutrophils 
(103/µl) 0.1 ± 0.01 0.2 ± 0.05 0.2 ± 0.04 
*P < 0.05 vs. wild-type, #P < 0.01 vs. wild-type, §P < 0.001 vs. wild-type mice. One-way ANOVA and post 
hoc Tukey’s test. Values are expressed as mean ± SEM. 
